Skip to main content

Table 2 Factors associated with imaging biomarkers of neurodegeneration related to Alzheimer’s disease

From: The contribution of vascular risk factors in neurodegenerative disorders: from mild cognitive impairment to Alzheimer’s disease

Dependent variable

Model

Independent variables

B estimate (95% CI)

Standardized β

P valueb

Hippocampal volume

I-1

Age

− 23.01 (− 28.71~ − 17.30)

− 0.414

< 0.001**

Gender

96.58 (− 9.99~203.15)

0.099

0.076

Educational level

− 3.93 (− 15.21~7.35)

− 0.038

0.494

APOEε4

− 174.78 (− 331.62~ − 17.93)

− 0.114

0.029*

Dyslipidemia

167.05 (58.20~275.89)

0.159

0.003**

Hippocampal volume

I-2

Age

− 22.67 (− 28.45~ − 16.88)

− 0.408

< 0.001**

Gender

89.25 (−17.90~196.40)

0.091

0.102

Educational level

− 1.97 (− 13.24~9.29)

− 0.019

0.731

APOEε4

− 158.91 (− 316.83~ − 1.00)

− 0.104

0.049*

Dyslipidemia: Group 3a

90.55 (9.06~172.04)

0.116

0.030*

White matter hyperintensity

II

Age

0.024 (0.017~0.032)

0.345

< 0.001**

Gender

− 0.129 (− 0.268~0.010)

− 0.104

0.068

Educational level

− 0.004 (− 0.019~0.011)

− 0.030

0.601

APOEε4

0.094 (−0.111~0.299)

0.048

0.4368

Hypertension

0.174 (0.040~0.309)

0.139

0.011*

Statin therapy

− 0.236 (− 0.386~ − 0.086)

− 0.167

0.002**

  1. Age, gender, educational level, and APOEε4 carrier status were adjusted as covariates in all linear regression models. Models were built by stepwise selection method with P value of entry = 0.1 and stay = 0.2
  2. Abbreviations: APOE apolipoprotein E, LDL low-density lipoprotein
  3. aDyslipidemia status was divided into four groups according to disease and treatment status: subjects without dyslipidemia (group 1), subjects with known dyslipidemia and received statin therapy (group 2), subjects with known dyslipidemia and not under medication control (group 3), and subjects unaware of their dyslipidemia status before enrollment (group 4)
  4. b* = P < 0.05, ** = P < 0.01